STOCK TITAN
  1. Home
  2. Sec-filings
  3. NVAX
  4. [Form 4] NOVAVAX INC Insider Trading Activity

Novavax (NVAX) EVP R&D awarded 99,500 options and 66,000 RSUs

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Novavax, Inc. EVP of R&D Robert Edward Walker received new equity compensation awards. He was granted stock options covering 99,500 shares of common stock at an exercise price of $8.46 per share, expiring on April 14, 2036.

The option vests 25% on the first anniversary of the April 14, 2026 grant date, with the remaining 75% vesting in equal monthly installments over the following three years, subject to continued employment. He also received 66,000 restricted stock units, each representing one share of common stock, vesting in three equal annual installments over three years, also contingent on continued employment.

Positive

  • None.

Negative

  • None.
Insider Walker Robert Edward
Role EVP, R&D
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 99,500 $0.00 --
Grant/Award Restricted Stock Units 66,000 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 99,500 shares (Direct); Restricted Stock Units — 6,600 shares (Direct)
Footnotes (1)
  1. Twenty-five percent (25%) of the shares subject to this option granted under the Novavax, Inc. (the "Company") Amended and Restated 2015 Stock Incentive Plan, as amended, vest on the first anniversary of the grant date, and the remaining seventy-five percent (75%) of the shares vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date. Each RSU represents a contingent right to receive one share of the "Company" common stock. The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the April 14, 2026 grant date, in each case subject to continued employment with the Company through such vesting date.
Stock options granted 99,500 shares Grant to EVP R&D on April 14, 2026
Option exercise price $8.46 per share Stock option grant strike price
Option expiration April 14, 2036 Stock option expiry date
RSUs granted 66,000 units Restricted Stock Units tied to common stock
Initial option vesting 25% after 1 year First anniversary of grant date
Remaining option vesting 75% over 3 years Equal monthly installments after first year
RSU vesting schedule 1/3 each year for 3 years On each anniversary of April 14, 2026
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
Restricted Stock Units financial
"security_title: "Restricted Stock Units""
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Amended and Restated 2015 Stock Incentive Plan financial
"granted under the Novavax, Inc. (the "Company") Amended and Restated 2015 Stock Incentive Plan"
vesting financial
"vest on the first anniversary of the grant date, and the remaining"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
contingent right financial
"Each RSU represents a contingent right to receive one share"
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Walker Robert Edward
(Last)(First)(Middle)
C/O NOVAVAX, INC.
21 FIRSTFIELD ROAD
(Street)
GAITHERSBURG MARYLAND 20878
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
NOVAVAX INC [ NVAX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
EVP, R&D
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/14/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$8.4604/14/2026A99,500 (1)04/14/2036Common Stock99,500$0.0099,500D
Restricted Stock Units(2)04/14/2026A66,000 (3) (3)Common Stock66,000$0.006,600D
Explanation of Responses:
1. Twenty-five percent (25%) of the shares subject to this option granted under the Novavax, Inc. (the "Company") Amended and Restated 2015 Stock Incentive Plan, as amended, vest on the first anniversary of the grant date, and the remaining seventy-five percent (75%) of the shares vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date.
2. Each RSU represents a contingent right to receive one share of the "Company" common stock.
3. The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the April 14, 2026 grant date, in each case subject to continued employment with the Company through such vesting date.
/s/ Mark J. Casey, Attorney-in-Fact04/16/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What equity awards did Novavax (NVAX) grant to EVP R&D Robert Walker?

Novavax granted Robert Walker stock options for 99,500 shares at $8.46 per share and 66,000 restricted stock units. These awards provide long-term equity incentives tied to continued employment and future stock performance.

How do Robert Walker’s new Novavax stock options vest?

The 99,500 stock options vest 25% on the first anniversary of the April 14, 2026 grant date. The remaining 75% vest in equal monthly installments over the next three years, assuming he remains employed at Novavax.

What are the terms of the restricted stock units granted to Novavax EVP R&D?

Robert Walker received 66,000 restricted stock units, each representing one Novavax common share. These RSUs vest in three equal annual installments on each of the first three anniversaries of the April 14, 2026 grant date, subject to continued employment.

What is the exercise price and expiration date of Robert Walker’s Novavax options?

The granted stock options have an exercise price of $8.46 per share and expire on April 14, 2036. They become exercisable over four years as they vest, aligning his potential gains with Novavax’s long-term share performance.

Are Robert Walker’s Novavax equity awards tied to continued employment?

Yes. Both the stock options and restricted stock units require continued employment at Novavax to vest. If employment ends before scheduled vesting dates, unvested options and RSUs may be forfeited under the plan’s terms.